Financials

Financials - The Margin That Defines the Stock

Molina is a $45 billion-revenue Medicaid-Medicare-Marketplace insurer whose 2025 results showed how thin the operating margin really is when the Medical Care Ratio (medical costs as a percentage of premium revenue) moves the wrong way. Premium revenue still grew 11% to $43.1 billion, but the consolidated MCR rose 260 basis points to 91.7%, and that single number compressed operating income from $1.71 billion to $781 million, halved net income, and turned a +$644 million operating cash inflow into a -$535 million outflow [1] [2] [3]. The stock has discounted the dislocation - a $100 invested at year-end 2020 was worth $80 at year-end 2025 versus $195 in the S&P 500 [4] - and the central question on the page is whether 2026 is the trough management says it is, or the start of a longer reset.

FY25 Total Revenue ($M)

$45,426

FY25 Operating Margin

1.7%

FY25 Diluted EPS

$8.92

FY25 Consolidated MCR (%)

91.7%

FY25 Free Cash Flow ($M)

-$636

FY25 Total Debt ($M)

$3,766

FY25 Net Debt ($M)

-$482

The terms a reader needs once. Premium revenue is what the company collects from Medicaid agencies, the federal government for Medicare, and Marketplace enrollees; it is the top of the funnel. Medical care costs are claims paid to doctors, hospitals, drug companies and other providers. Medical Care Ratio (MCR) = medical care costs / premium revenue - a single percent of MCR change at Molina's premium base is roughly $430 million of pretax profit at risk. Medical margin = premium revenue minus medical care costs - the analogue of "gross profit" for a health insurer. G&A ratio = general and administrative expense / total revenue, the leverage metric on top of medical margin [1].

The Standard Year-Wise Statements (FY2016-FY2025)

No Results

Reading the table. Two distinct chapters. FY2016-FY2018 captures the post-ACA volatility and the 2017 management reset (operating loss of $555 million after Marketplace cost overruns); FY2019-FY2024 is the Zubretsky-led re-platforming - revenue compounded at ~19% per year over five years, ROE held in the 25-37% band, and EPS roughly doubled [5]. FY2025 is the rupture: revenue still grew, but operating income, EPS, OCF, FCF, equity and ROE all moved the wrong way at once. That convergence - not any single line - is why the equity got marked down.

What Actually Broke in 2025 (and Why It Matters More Than the Revenue Headline)

Premium revenue rose $4.4 billion to $43.1 billion in 2025, mostly from the ConnectiCare acquisition that closed February 1, Medicaid rate increases, and Marketplace growth from the company's pricing strategy [2] [6]. The problem is that medical care costs grew faster than premiums in every segment.

No Results

Three causes were called out by management:

Medicaid MCR up 150 bps to 91.8% on higher unit costs (behavioral health, high-cost drugs, professional outpatient) and acuity shifts left over from the post-pandemic redetermination process - rates lag the trend by 6-12 months [7].
Medicare MCR up 330 bps to 92.4%, driven by high-acuity duals utilization (Long-Term Services and Support, high-cost pharmacy) and margin compression in the MAPD product Molina is exiting in thirteen states [8].
Marketplace MCR exploded 1,520 bps to 90.6% from 75.4%, reflecting Special Enrollment Period acuity, ConnectiCare's higher starting MCR, and CMS program integrity initiatives that disenrolled members but left Molina paying their claims [8].

Two transcript disclosures put a number on how unusual one piece of this was. The Q4 2025 call quantified ~$135 million ($2 per share) of "unusual" California-specific items - a state-funded undocumented-immigration risk corridor adjustment that CMS would normally block, plus an LA County risk-adjustment data refresh that came out unfavorably [9]. Management then chose to pull a similar amount of conservatism into 2026 guidance, taking the implied earnings frame from "$14 per share" down to "$5 per share" [9].

The arithmetic of MCR for a low-margin insurer. At a $43 billion premium base, every 100 basis points of MCR is ~$430 million of pretax income at risk. The 260 bps move in 2025 explains roughly $1.1 billion of pretax compression on its own - close to the entire reported drop in operating income from $1.71 billion to $781 million [1].

The Quarterly Trajectory - and What Q1 2026 Says

EPS held above $4 through Q2 2025 before collapsing in the back half. Q3 dropped to $1.51 and Q4 swung to a $3.15-per-share loss as Molina booked the California adjustments and absorbed the full force of the cost-trend reset [10]. Q1 2026 came in at $0.27 - "strong when compared to internal and external expectations," per CEO Joseph Zubretsky, with operating cash flow of $1.1 billion in the quarter and management merely reaffirming the full-year guide of at least $5 of adjusted EPS on roughly $42 billion of premium [11] [12].

Earnings Quality - Where Net Income Stopped Becoming Cash

For a managed-care company, operating cash flow is intrinsically lumpy: premiums come in monthly and in advance, while medical-cost settlements (risk corridors, MLR rebates, CMS program-integrity reconciliations) can swing meaningfully across periods. Even allowing for that, the FY2025 print is unusual. Net cash used in operations was $535 million versus $644 million provided in 2024 - a $1.18 billion year-over-year swing. Management attributes it to lower operating income, the settlement timing of Medicaid minimum MLR / medical-cost corridor receivables and payables, Marketplace risk-adjustment payables, and tax-payment timing [3].

CFO Mark Keim's caution on the Q1 2026 call is worth holding: "in a regulated business like Molina, what's more important than total company operating cash flow is cash flow at the parent… operating cash flow swings a lot as we do accruals for risk adjustment for corridors" [13]. The Q1 2026 number - $1.1 billion of OCF in a single quarter - shows the corridor settlements can also reverse with the same force [12].

The picture across a decade is therefore more reassuring than the single-year cash hole suggests: FY2020-FY2024 generated cumulative free cash flow of $6.7 billion against cumulative net income of $4.4 billion, a 152% cash conversion ratio. But FY2025 broke that streak, and the question for FY2026 is whether the corridor receivable build-up reverses in cash terms (the Q1 print says yes, so far) or compounds.

Capex is structurally trivial - $101 million in 2025 on $45.4 billion of revenue, ~22 bps - which is normal for an insurer. Free cash flow at Molina is essentially operating cash flow.

Share-based compensation is also unusually small for a $10 billion-market-cap company. SBC pretax was $47 million in 2025, down from $116 million in 2024, with the drop driven by lower management incentive accruals against the weaker year [14]. Dilution from compensation is minor; the share count moves come from buybacks.

Balance Sheet - The One Part That Held Up

Even after the worst earnings year of the new era, Molina still ended 2025 with $4.2 billion of cash plus $4.0 billion of short-term investments against $3.77 billion of total long-term debt - a net cash position of roughly $482 million. Of course, most of that cash is captive at the regulated subsidiaries; only $223 million sat at the parent at year-end (versus $445 million the year prior), and only ~$170 million of subsidiary dividends could be paid without regulatory approval as of Dec 31, 2025 [15] [16]. The regulated subs still paid the parent $985 million of dividends in 2025 (vs $997 million in 2024), so the cash-up pipeline is intact - but lower 2025 net income will mechanically compress 2026 dividend capacity [15] [16].

No bond matures before 2028, and the most recent issuance was a November 2025 $850 million print of 6.500% notes due 2031 that took out a $740 million term loan from the old credit agreement [17]. At the same time, Molina entered a new $1.25 billion revolving credit facility with a November 2030 termination, drawn at zero at year-end, plus $800 million of incremental term-loan capacity for acquisitions [18]. Management also "secured an agreement with our bank syndicate to appropriately amend" the debt-covenant metrics in light of weaker 2026 EBITDA - i.e. a proactive covenant amendment ahead of the trough rather than a forced renegotiation [10]. Trailing-12-month debt/EBITDA was 3.7x at year-end 2025; the CFO has flagged that ratio drifting to 6.1x by Q1 2026 on the rolling EBITDA denominator and debt-to-cap at 47-48% versus a "low 40s" sustaining target [10] [12].

The weighted-average coupon on the new $3.8 billion debt stack is in the mid-5s; interest expense was $192 million in 2025, up from $118 million in 2024, on the heavier balance and the higher 2031/2033 coupons [1]. Aggregate RBC capital at the subsidiaries was 305%, more than 50% above state minimums - solvency at the regulated entity is not the issue [10].

Goodwill rose to $1.96 billion at year-end 2025 from $1.67 billion, the entire increase coming from the ConnectiCare deal (Marketplace +$220M, Medicare +$67M) [19]. Cost of acquisition was $350 million for ~140,000 members across Marketplace, Medicare and certain commercial products [6]. With Marketplace MCR running where it ran in 2025, the deal is unlikely to look like a vintage steal, but no impairment has been recorded.

Capital Allocation - $1 Billion Returned Through a Down Year

Molina pays no dividend and never has [20]. The full capital-return story is buybacks, and it ran straight through the 2025 storm.

Molina repurchased $1.0 billion of stock in 2025 - roughly 1.7 million shares for $500 million in Q1 and 2.8 million shares for $500 million in Q3, working the diluted share count from 57.7 million down to 52.9 million [15] [1]. The Q1 tranche cleared near $294 per share and the Q3 tranche near $179; with the stock now around $195, the Q3 buyback already looks neutral-to-positive while the Q1 cohort is materially underwater - a reminder that running aggressive buybacks alongside a covenant-amending year of negative FCF carried real opportunity cost. In April 2025 the board authorized an additional $1.0 billion of repurchase capacity through December 31, 2026; $500 million of that remained available as of the FY25 10-K filing date [18].

The other use of capital is M&A. ConnectiCare ($350 million purchase price, ~140,000 members) was the only sizable 2025 deal; management calls the acquisition pipeline "a growing number of actionable opportunities," and the 10-K explicitly cites organic growth from RFP wins as the company's "highest priority" [6] [18]. Collectively, newly reported 2025 RFP wins plus acquisitions represent nearly $9 billion of incremental annual premium revenue as those contracts ramp in 2026 and beyond - real top-line momentum to set against the margin reset [21].

Returns on Capital - The Real Casualty of 2025

For most of FY2018-FY2024 Molina was a 25-37% ROE business, a remarkable level for any insurer and a function of low capital intensity, high asset turnover (~2.6x), and operating margins in the high-3% to 6% range applied to a $30-40 billion revenue base [22]. The fall to 11.6% ROE in 2025 is not a small downshift; it is more than a halving of the franchise's earned return on the equity base [1]. Whether the next 24 months see a snap-back to high-20s or a multi-year journey back is the central long-only debate.

Peer Comparison - Everyone in Managed Care Is Hurting, But Differently

No Results

Three readings.

First, the 2025 reset is sector-wide, not Molina-specific. Centene swung to a -$6.7 billion net loss (net margin -3.8%, ROE -33%); Humana's net margin barely cleared 0.9% and ROE compressed to 6.7%; Elevance held a 12.9% ROE but with margins under pressure. The two large diversified peers (UnitedHealth and CVS) carry their own franchise problems, but on net margin and revenue scale both look more durable than the pure-play managed-care peers.

Second, Molina ran the smallest dollar revenue (~$45 billion) but the highest historical capital efficiency. Even after the FY25 reset, its 11.6% ROE in the worst year of the cycle sits between Humana (6.7%) and Elevance (12.9%) and well above the loss-making Centene. The high-asset-turn / low-capital-base business model that produced 25%+ ROEs in the good years is structurally intact - it just gets exposed when MCR moves against it.

Third, leverage is the most binary signal in the table. Molina's debt-to-equity at 0.93x is now the highest among the peers reporting a positive denominator, a function of stable debt levels plus equity compression from a weak earnings year and a $1 billion buyback. UNH, CI and CVS each report essentially zero traditional debt-to-equity ratios (their leverage shows up in other forms), making Molina's balance sheet, in relative terms, the second-tightest in the comp set after Centene.

Valuation - At $195, What Are You Paying For?

Price (Jun 18, 2026)

$194.76

P/E (TTM, FY25 EPS $8.92)

21.8

P/E (FY26 Est, $5.16)

37.7

P/E (FY27 Est, $8.07)

24.1

EV / FY25 Revenue (x)

0.23

Consensus Target ($)

$190.25

At $194.76, Molina trades at 21.8x trailing FY25 EPS, 37.7x consensus FY26 EPS of $5.16, and 24.1x consensus FY27 EPS of $8.07. The 5-year cumulative return table the company itself published shows MOH worth $80 at year-end 2025 on a $100 base at the start of 2021, against $195 for the S&P 500 - the equity has already lived through a deep de-rating [4]. EV-to-revenue at 0.23x is unusually low even for a low-margin business; against UNH's 0.82x or ELV's 0.42x it looks like a discount, but multiples on revenue are only meaningful in light of the margin that revenue produces.

Three ways to read the multiple.

If 2026 is the trough management says it is, $5 of EPS becomes a floor, the rate cycle restores Medicaid margins to the company's long-term target range (Medicaid pretax around 4-5% per Molina's normalized algorithm), and EPS pivots back toward the $14-15 range from FY24 by 2027-2028. On that path, today's price is roughly 13-14x normalized earnings - genuinely cheap if the algorithm holds, and the FY27 P/E of 24x sits between trough and normal. Management explicitly framed FY26 as "the trough for managed Medicaid margins" and quantified the leverage: "every 100 basis points on the Medicaid MCR is worth nearly $5 per share," with "embedded earnings… now greater than $11 per share" from contract wins not yet at target margin [23].
If the cycle takes longer, FY27 EPS lands closer to consensus' $8 than to $14, today's multiple is mid-20s on a still-suppressed number, and the stock has a long flat period.
If the OBBBA-driven 15-20% Medicaid Expansion attrition compounds, the premium base shrinks even as MCR normalizes; revenue falls, dividend capacity at subs declines, and the leverage ratio that already drifted to 6.1x trailing EBITDA in Q1 2026 keeps the equity story constrained [24] [12].

The consensus mean price target of $190.25 sits essentially on top of the current quote - the sell side has effectively marked the stock to the FY27 P/E discounted by the residual cycle risk.

The View

Molina is a high-quality franchise (proven 25%+ ROE in normal years, $9 billion of incremental premium teed up from 2025 wins, no maturities before 2028, no dividend obligation, regulated solvency well above minimums) going through a low-quality earnings year. The financial case turns almost entirely on a single number - the Medical Care Ratio, especially in Medicaid - because the business model carries so little operating margin that the MCR mathematically is the earnings. The balance sheet is firmer than the income statement suggests, but it is also tighter than it was twelve months ago (debt up, equity down, leverage covenants proactively amended). The bullish case is: 2026 is a trough, rates restore, embedded earnings from new contract wins land, and a 21x-trailing multiple on a return-to-form number proves cheap. The bearish case is: redetermination acuity, OBBBA work requirements, and a deliberately shrunken Marketplace book mean revenue and dividend capacity step down before MCR normalizes - and the parent's $223 million of cash, with subsidiary dividends mechanically dropping in 2026, looks thinner against a $1 billion-a-year buyback cadence and $192 million of interest.

The first financial metric to watch is the FY2026 Medicaid Medical Care Ratio, with a specific marker at the company's own guide of 92.9%. A print materially below 92.9% as the year develops - especially in 3Q and 4Q after the rate cycle takes effect - validates management's "trough" framing and underwrites a snap-back in EPS toward double digits. A print at or above 92.9% extends the cycle, keeps EPS pinned near $5, and forces another reset in valuation expectations.

References

Generated Jun 19, 2026 10:03 UTC